Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TYRA-200 in Advanced Intrahepatic Cholangiocarcinoma and Other Solid Tumors With Activating FGFR2 Gene Alterations
NCT06160752Phase 1Active, not recruiting
- Sponsor
- Tyra Biosciences
- Start
- Nov 2023
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TYRA-200 in intrahepatic cholangiocarcinoma (ICC) and solid tumor, sponsored by Tyra Biosciences. Primary endpoints: Maximum Tolerated Dose at 28 days and Optimal Dose up to 18 months. Started Nov 2023; status: active, not recruiting.
02
Drugs
TYRA-200
03
Conditions
intrahepatic cholangiocarcinoma (ICC)solid tumor
Beyond the preview
Go deeper on NCT06160752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06160752.